House of Commons · Written Ministerial Statement
Covid-19 Update
07 February 2024 · Department of Health and Social Care
Proposed by Maria Caulfield Con Lewes
Summarised by AI from the official record, so it can contain mistakes.
At a glance
Key points
- The Joint Committee on Vaccination and Immunisation (JCVI) has provided latest advice on the spring 2024 COVID-19 vaccination programme.
- HM Government has accepted JCVI's recommendation to provide an additional dose of the XBB-variant vaccines to individuals at highest risk.
- The UK's four nations plan to adhere to this guidance for their vaccine deployment.
Issue summary
The statement addresses the latest advice from the Joint Committee on Vaccination and Immunisation (JCVI) regarding the spring 2024 COVID-19 vaccination programme.
Action requested
HM Government has accepted JCVI's advice to offer a further dose of the latest XBB-variant vaccines in spring 2024 to those at greatest risk, with all four parts of the UK intending to follow this guidance. The statement also notes that HMG is updating liabilities for vaccine deployment and considering cost-effectiveness in future programmes.
Key facts
- JCVI advises offering a further dose of COVID-19 vaccines in spring 2024 to those aged 75 years and above.
- The minimum gap between doses should be around 6 months after the last vaccine dose with a minimum interval of 3 months.
- XBB-variant and mRNA Omicron XBB.1.5 vaccines are considered most cost-effective for use in spring 2024.